123 Using a scenario approach to assess for the current and future demand of immunoglobulins 74. Bhella S, Majhail NS, Betcher J, et al. Choosing wisely BMT: American Society for Blood and Marrow Transplantation and Canadian blood and marrow transplant Group’s list of 5 tests and treatments to question in blood and marrow transplantation. Biol Blood Marrow Transplant. 2018;24(5):909-913. 75. Strengers PFW. Evidence-based clinical indications of plasma products and future prospects. Ann Blood. 2017;2:20. 76. Broers MC, van Doorn PA, Kuitwaard K, et al. Diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in clinical practice: a survey among Dutch neurologists. J Peripheral Nervous Syst JPNS. 2020;25(3):247-255. 77. Wiesik-Szewczyk E, Sołdacki D, Paczek L, Jahnz-Ro’żyk K. Facilitated subcutaneous immunoglobulin replacement therapy in clinical practice: a two center, long-term retrospective observation in adults with primary Immunodeficiencies. Front Immunol. 2020;11:981. 78. Rajabally YA. Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects. J Neurol Neurosurg Psychiatry. 2014;85(6):631-637. 79. Ducruet T, Levasseur MC, Des Roches A, Kafal A, Dicaire R, Haddad E. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric cen- ter. J Allergy Clin Immunol. 2013;131(2):585-587.e3. 80. Perraudin C, Bourdin A, Vicino A, Kuntzer T, Bugnon O, Berger J. Home-based subcutaneous immunoglobulin for chronic inflamma- tory demyelinating polyneuropathy patients: a Swiss cost- minimization analysis. PloS One. 2020;15(11):e0242630. 81. Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency. Vox Sang. 2019;114(3):237-246. 82. Grabowski HG, Manning RL. An economic analysis of global policy proposals to prohibit compensation of blood plasma donors. Int J Econ Bus. 2016;23(2):149-166. 83. Godin G, Germain M. Predicting first lifetime plasma donation among whole blood donors. Transfusion. 2013;53(Suppl 5):157S- 161S. 84. Van Dongen, Veldhuizen I. Motivational differences between whole blood and plasma donors already exist before their first donation experience. Transfusion. 2013;53(8):1678-1686. 85. Strengers PF, Klein HG. Plasma is a strategic resource. Transfusion. 2016;56(12):31333137. 86. Farrugia A, Cassar J. Plasma-derived medicines: access and usage issues. Blood Transfus. 2012;10(3):273-278. 87. Farrugia A. Are we optimising outcomes in Australia’s framework for the supply of plasma-derived medicines? Med J Aust. 2016; 205(7):336.
RkJQdWJsaXNoZXIy MTk4NDMw